Literature DB >> 8853285

Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy.

P J Thornalley1.   

Abstract

1. Methylglyoxal is a reactive alpha-oxoaldehyde and physiological metabolite formed by the fragmentation of triose-phosphates, and by the metabolism of acetone and aminoacetone. 2. Methylglyoxal modifies guanylate residues to form 6,7-dihydro-6,7-dihydroxy-6-methyl-imidazo[2,3-b]purine-9(8)one and N2-(1-carboxyethyl)guanylate residues and induces apoptosis. 3. Methylglyoxal modifies arginine residues in proteins to form N(delta)-(4,5-dihydroxy-4-methylimidazolidin-2-yl) ornithine, N(delta)-(5-hydro-5-methylimidazol-4-on-2-yl)ornithine and N(delta)-(5)methylimidazol-4-on-2-yl)ornithine residues. 4. Methylglyoxal-modified proteins undergo receptor-mediated endocytosis and lysosomal degradation in monocytes and macrophages, and induce cytokine synthesis and secretion. 5. Methylglyoxal is detoxified by the glyoxalase system. Decreased detoxification of methylglyoxal may be induced pharmacologically by glyoxalase I inhibitors which have anti-tumor and anti-malarial activities. 6. The modification of nucleic acids and protein by methylglyoxal is a signal for their degradation and may have a role in the development of diabetic complications, atherosclerosis, the immune response in starvation, aging and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853285     DOI: 10.1016/0306-3623(95)02054-3

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  147 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

2.  Genetic and pharmacological manipulation of glyoxalase 1 regulates voluntary ethanol consumption in mice.

Authors:  Katherine M J McMurray; Preetpal S Sidhu; James M Cook; Leggy A Arnold; Abraham A Palmer
Journal:  Addict Biol       Date:  2015-12-22       Impact factor: 4.280

Review 3.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

4.  Tumour necrosis factor induces phosphorylation primarily of the nitric-oxide-responsive form of glyoxalase I.

Authors:  Virginie de Hemptinne; Dieter Rondas; Joël Vandekerckhove; Katia Vancompernolle
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

5.  Ribose utilization with an excess of mutarotase causes cell death due to accumulation of methylglyoxal.

Authors:  Insook Kim; Eunjung Kim; Seokho Yoo; Daesung Shin; Bumchan Min; Jeeyeon Song; Chankyu Park
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

Review 6.  Oxidative stress as a mechanism of added sugar-induced cardiovascular disease.

Authors:  Kailash Prasad; Indu Dhar
Journal:  Int J Angiol       Date:  2014-12

7.  Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats.

Authors:  Arti Dhar; Kaushik M Desai; Lingyun Wu
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

8.  Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

Authors:  Helen Vlassara; Jaime Uribarri; Luigi Ferrucci; Weijing Cai; Massimo Torreggiani; James B Post; Feng Zheng; Gary E Striker
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

9.  Management of oxidative stress in the CNS: the many roles of glutathione.

Authors:  B H Juurlink
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

10.  Reactive intermediates: molecular and MS-based approaches to assess the functional significance of chemical-protein adducts.

Authors:  Terrence J Monks; Serrine S Lau
Journal:  Toxicol Pathol       Date:  2012-12-06       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.